Eptinezumab (Vyepti®): A Quarterly Infusion to Prevent Migraine

Eptinezumab (Vyepti®): An intravenous preventive treatment for migraine

Eptinezumab (Vyepti®) is a CGRP monoclonal antibody used to prevent migraine. It is given by intravenous infusion once every 3 months.

At the Ottawa Headache Centre, we use intravenous CGRP therapy like Vyepti® selectively in patients with high migraine burden who prefer to avoid daily medications, and when structured infusion care provides advantages.

Looking for a detailed medication handout of Vyepti®? Explore our downloadable handouts created by the specialists at the Ottawa Headache Centre.

Expedited access to Vyepti® in Ottawa - a unique offering at the Ottawa Headache Centre

At the Ottawa Headache Centre, we offer expedited initiation of eptinezumab (Vyepti®) for carefully selected patients with severe migraine burden. This may include patients with:

High frequency of migraine attacks with either episodic or chronic migraine
Status migrainosus in spite of trialing preventives
Refractory attacks to oral preventives
Prolonged or difficult-to-break migraine episodes
Significant functional impairment

All treatment decisions are made following neurologist and specialist assessment.

Ask your doctor for a referral to the Ottawa Headache Centre to learn more.

Getting started on eptinezumab (Vyepti®) in Ottawa

Who may benefit from eptinezumab (Vyepti®)?

Eptinezumab (Vyepti®) is used for the prevention of episodic or chronic migraine. It is administered via a short intravenous infusion once every three months.

We consider eptinezumab (Vyepti®) when:

Patients continue to have frequent migraine attacks after trying two oral preventives
Pregnancy is not foreseeable for at least 6 months
There is a preference for infrequent dosing rather than taking a medication every day
There is a preference to not self-inject a treatment at home

How do you access eptinezumab (Vyepti®) in Ottawa?

In Ontario, coverage for eptinezumab (Vyepti®) often requires:

A diagnosis of episodic or chronic migraine
Documentation of migraine frequency
Trials of at least two oral preventive medications at therapeutic doses (usually for ~3 months each, depending on insurer)

People without private insurance may be eligible to have the cost of eptinezumab (Vyepti®) reimbursed through an application to the Exceptional Access Program (this can be done by any doctor).

At the Ottawa Headache Centre we will:

Confirm your diagnosis and migraine burden
Determine whether eptinezumab (Vyepti®) is an appropriate option, and offer alternatives
Discuss the evidence backing eptinezumab (Vyepti®), its benefits, as well as side-effects
Assist with any insurance forms
Complete the prior authorization process that is needed

Next steps to get started on eptinezumab (Vyepti®) in Ottawa

If you feel like you are getting nowhere with your migraine preventives, ask your doctor for a referral to the Ottawa Headache Centre and we will explore migraine-specific preventive options with you.

Eptinezumab (Vyepti®) and its effect on migraine

Eptinezumab (Vyepti®) is a monoclonal antibody that binds to CGRP in the bloodstream, preventing it from activating migraine pain pathways.

By reducing CGRP activity, eptinezumab (Vyepti®):

Lowers the likelihood that a migraine attack will occur.

Decreases the severity and duration of migraine attacks.

Makes migraine attacks more susceptible to acute medications (i.e., easier to treat).

Next steps

Eptinezumab (Vyepti®) can be an excellent option for migraine prevention depending on your diagnosis, migraine pattern, prior treatment history, preferences, and lifestyle values.

If you are considering Vyepti® (or have been referred), our consultation helps:

confirm whether eptinezumab (Vyepti®) fits your migraine profile
set realistic timelines for judging response
and place it into a broader, individualized care plan (including acute and non-medication strategies).

Ask your doctor for a referral to the Ottawa Headache Centre if you want to learn more about your migraine-specific preventive options.

Common questions about eptinezumab (Vyepti®)

How is eptinezumab (Vyepti®) administered?

Eptinezumab (Vyepti®) is administered via an intravenous (IV) infusion every 12 weeks.

The infusion takes about 30 minutes and is given in a supervised medical setting.

How quicky does eptinezumab (Vyepti®) work?

Eptinezumab (Vyepti®) generally begins to have effect within days and full benefit may continue to improve over several weeks.

A large study demonstrated that eptinezumab (Vyepti®) given during a migraine attack could have a rapid effect within hours for some people.

What are the side effects of eptinezumab (Vyepti®)?

Eptinezumab (Vyepti®) is generally well tolerated.

Possible side effects:

Injection-site reactions (redness, soreness)
Constipation
Muscle or joint aches (uncommon)
Fatigue (uncommon)
Urinary tract infections or nasopharyngitis (rare)

Serious allergic reactions are rare.

Does eptinezumab (Vyepti®) affect the immune system?

No.
Eptinezumab (Vyepti®):

Does not suppress the immune system
Does not increase infection risk
Is not considered an immunosuppressive therapy

Can eptinezumab (Vyepti®) be used during pregnancy?

CGRP monoclonal antibodies including eptinezumab (Vyepti®) are not recommended during pregnancy due to limited safety data.

If pregnancy is planned:

These medications should be stopped at least 6 months before pregnancy

This allows time for the medication to fully clear from the body.

If you are pregnant or planning pregnancy, we will help you find alternative migraine strategies.

Can eptinezumab (Vyepti®) be used during breastfeeding or lactation?

Data on breastfeeding are limited but growing, and expert consensus is that CGRP monoclonal antibodies' expression in breast-milk is low, the amount of drug an infant may consume and ultimately absorb is trivial. Decisions are individualized based on:

Migraine severity
Available alternatives
Patient preferences

We help guide these discussions using the best available evidence.

Is eptinezumab (Vyepti®) covered for migraine in Ontario?

In Ontario, coverage for eptinezumab (Vyepti®) often requires:

A diagnosis of episodic or chronic migraine
Documentation of migraine frequency
Trials of at least two oral preventive medications at therapeutic doses (usually for ~3 months each, depending on insurer)

People without private insurance may be eligible to have the cost of eptinezumab (Vyepti®) reimbursed through an application to the Exceptional Access Program.

We assist with:

Insurance forms
Prior authorization

Can eptinezumab (Vyepti®) be combined with other treatments?

From a medical perspective, eptinezumab (Vyepti®) can be used:

Alone
Alongside other oral preventive medications
Concurrently with Botox® for chronic migraine, although insurers will typically not cover both

Insurance plans may restrict coverage of combination advanced therapies.

Can gepants be combined with eptinezumab (Vyepti®)?

From a medical perspective, it is safe to combine eptinezumab (Vyepti®) and gepants although the combination may increase the risk of constipation.

Insurance plans may restrict coverage of combining a preventive gepant - like atogepant (Qulipta ®) and CGRP monoclonal antibodies..

What happens if eptinezumab (Vyepti®) works?

If eptinezumab (Vyepti®) is effective:

Treatment is continued
There is no monitoring required
Many patients can transition prescription renewal to their family physician
Treatment may be discontinued 1-2 years later to revaluate whether it needs to be continued

If I did not respond to one CGRP antagonist, does that mean that I won't respond to any?

No.

For many people it takes a few trials to find the most effective migraine preventive, and some people who have not responded to one CGRP antagonist respond to a different one. It is not uncommon to cycle through different treatment options until we find the one that is right for you.

Disclaimer

This material is provided for educational purposes and does not replace independent clinical judgment or institutional protocols. Management decisions remain the responsibility of the treating clinician.

Page updated

Google Sites

Report abuse